Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
View Patent ↗Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
1. A method of treating excess mucus accumulation in a mammal's airway comprising:
providing a pressurized source of nitric oxide containing gas; and
administering through inhalation a therapeutically effective amount of nitric oxide containing gas to a mammal exhibiting excess mucus accumulation in the mammal's airway, wherein the nitric oxide containing gas is administered substantially coincident with the inspiration of the mammal, resulting in the flow of non-viscous liquids and mucus reduction.
2. The method of claim 1 , further comprising the step of regulating a flow rate of the nitric oxide containing gas depending on the mammal's respiratory tidal volume.
3. The method of claim 2 , wherein the concentration of nitric oxide gas in the mammal's airway ranges from about 160 ppm to about 220 ppm.
4. The method of claim 1 , wherein the administration of the nitric oxide containing gas is timed according to a synchronous parameter of the mammal's respiratory cycle.
5. The method of claim 4 , wherein the synchronous parameter is selected from a group consisting of rate of flow of gas directed toward the mammal's airway, pressure change at the initiation of a breath, the synchronous movement of the laryngeal, and the synchronous motion of the chest wall.
6. The method of claim 1 , wherein the therapeutically effective amount of nitric oxide containing gas is sufficient to reduce an amount of mucus in the mammal's airways by at least 50%.
7. The method of claim 1 , wherein the therapeutically effective amount of nitric oxide containing gas is sufficient to effect mucolysis within thirty minutes.
8. The method of claim 1 , wherein the mammal is a horse.
9. A method of treating excess mucus accumulation in a mammal's airway comprising:
identifying a mammal exhibiting excess mucus accumulation;
determining the severity of mucus accumulation in the mammal;
providing a source of nitric oxide containing gas; and
administering through inhalation the nitric oxide containing gas using a distinct therapeutic profile corresponding to the severity of mucus accumulation in the mammal, resulting in the flow of non-viscous liquids and mucus reduction.
10. The method of claim 9 , wherein the severity of mucus accumulation is scored from 0 to 5, with 5 indicating a most severe condition.
11. The method of claim 9 , wherein the distinct therapeutic profile is selected from a pre-determined set of therapeutic profiles.
12. The method of claim 11 , wherein the distinct therapeutic profile comprises therapeutic parameters selected from a group consisting of flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
13. The method of claim 9 , wherein the mammal is a horse.
14. A method of treating excess mucus accumulation in a mammal's airway comprising:
administering through inhalation a therapeutically effective amount of NO-releasing compounds to a mammal exhibiting excess mucus accumulation in the mammal's airway, resulting in the flow of non-viscous liquids and mucus reduction.
15. The method of claim 14 , wherein the NO-releasing compounds is selected from a group consisting of S-nitrosothiols, S-nitroso-N-acetylpenicillamine, S-nitroso-L-cysteine, NONOates, nitroprusside, NO-ferredoxin, NO-heme complex, and nitrosoguanidine.
16. The method of claim 14 , wherein the mammal is a horse.
17. The method of claim 14 , wherein the therapeutically effective amount of NO-releasing compounds is sufficient to reduce an amount of mucus in the mammal's airways by at least 50%.
18. The method of claim 14 , wherein the therapeutically effective amount of NO-releasing compounds sufficient to effect mucolysis within thirty minutes.
19. A method of treating excess mucus accumulation in a mammal's airway comprising:
identifying a mammal exhibiting excess mucus accumulation;
determining the severity of mucus accumulation in the mammal; and
administering through inhalation NO-releasing compounds using a distinct therapeutic profile corresponding to the severity of mucus accumulation in the mammal, resulting in the flow of non-viscous liquids and mucus reduction.
20. The method of claim 19 , wherein the NO-releasing compounds is selected from a group consisting of S-nitrosothiols, S-nitroso-N-acetylpenicillamine, S-nitroso-L-cysteine, NONOates, nitroprusside, NO-ferredoxin, NO-heme complex, and nitrosoguanidine.
21. The method of claim 19 , wherein the severity of mucus accumulation is scored from 0 to 5, with 5 indicating a most severe condition.
22. The method of claim 19 , wherein the distinct therapeutic profile is selected from a pre-determined set of therapeutic profiles.
23. The method of claim 19 , wherein the mammal is a horse.
24. The method of claim 19 , wherein the therapeutically effective amount of NO-releasing compounds is sufficient to reduce an amount of mucus in the mammal's airways by at least 50%.
25. The method of claim 19 , wherein the therapeutically effective amount of NO-releasing compounds sufficient to effect mucolysis within thirty minutes.